Repligen to Report First Quarter 2017 Financial Results
April 21 2017 - 7:30AM
Repligen Corporation (NASDAQ:RGEN) today announced that the Company
will report first quarter of 2017 financial results on Thursday,
May 4, 2017. The Company will issue a press release before the
market opens and will host a conference call at 8:30 a.m. EDT to
discuss business updates and financial results for the reporting
periods ended March 31, 2017.
The conference call will be accessible by
dialing toll-free (844) 835-7432 for domestic callers and (404)
537-3372 for international callers. Dial-in participants must
provide the passcode 11424546. In addition, a webcast will be
accessible via the Investor Relations section of the Company's
website. Both the conference call and webcast will be archived for
a period of time following the live event. The replay dial-in
numbers are (855) 859-2056 for domestic callers and (404) 537-3406
for international callers. Replay listeners must provide the
passcode 11424546.
About Repligen
CorporationRepligen Corporation (NASDAQ:RGEN) is a
bioprocessing company focused on the development, manufacture and
commercialization of highly innovative products used to improve the
interconnected phases of the biological drug manufacturing process.
Our portfolio includes protein products (Protein A affinity
ligands, cell culture growth factors), chromatography products
(OPUS® pre-packed columns, chromatography resins, ELISA kits) and
filtration products (XCell™ ATF Systems, TangenX™ Sius™ TFF
cassettes). Our bioprocessing products are sold to major life
sciences companies, biopharmaceutical development companies and
contract manufacturing organizations worldwide. The Protein A
ligands and growth factor products that we manufacture are
components of chromatography resins and cell culture media,
respectively. We are the leading manufacturer of Protein A ligands,
a critical component of Protein A resins that are the industry
standard for downstream separation and purification of monoclonal
antibody-based therapeutics. Our growth factors are used in
upstream processes to accelerate cell growth and productivity. Our
innovative line of OPUS® chromatography columns, used in downstream
processes for bench-scale through clinical-scale purification
needs, are delivered pre-packed with our customers' choice of resin
and bed height. Our XCell™ ATF Systems, available in stainless
steel and single-use configurations, continuously eliminate waste
from a bioreactor to concentrate cells and increase productivity in
upstream processes. Single-use Sius™ TFF cassettes and hardware are
used for biologic drug concentration in downstream processes.
Repligen's corporate headquarters are in Waltham, MA (USA) and our
manufacturing facilities are located in Waltham, MA, Shrewsbury,
MA, Lund, Sweden and Weingarten, Germany.
This press release may contain forward-looking
statements within the meaning of the federal securities laws.
Investors are cautioned that statements in this press release which
are not strictly historical statements including, without
limitation, statements identified by words like "believe,"
"expect," "may," "will," "should," "seek," or "could" and similar
expressions, constitute forward-looking statements. Such
forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results to differ materially
from those anticipated, including risks discussed from time to time
in our filings with the Securities and Exchange Commission. We
expressly disclaim any responsibility to update any forward-looking
statements, except as required by law.
Contact:
Sondra Newman
Senior Director Investor Relations
(781) 419-1881
snewman@repligen.com
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Apr 2024 to May 2024
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From May 2023 to May 2024